ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models: Initial Results from an Ongoing Phase I/II Safety and Preliminary Efficacy Study in Severe PAH

Home ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models: Initial Results from an Ongoing Phase I/II Safety and Preliminary Efficacy Study in Severe PAH

ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models: Initial Results from an Ongoing Phase I/II Safety and Preliminary Efficacy Study in Severe PAH

/ Publications

Share the Post

About the Author

Related Posts

Read More
Behzad Aghazadeh, PhD
Response to Treatment With nab-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECT 
Patients With Severe Pulmonary Arterial Hypertension Treated With ABI-009, nab-Sirolimus, an mTOR Inhibitor: Interim Results From a Phase 1 Clinical Trial
Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database
Severe Pulmonary Arterial Hypertension Treated with ABI-009, nab-Sirolimus, an mTOR Inhibitor
Baiteng Zhao, PhD
Long-term follow-up for duration of response (DOR) after weekly nab-sirolimus (ABI-009) in patients with advanced malignant perivascular epitlhelioid cell tumors (PEComa): Results from a registrational open-label phase 2 trial, AMPECT
Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)

Comments

Comments are closed.